ClinicalTrials.gg
RecruitingNCT07863141Updated Oct 7, 2026

A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)

A Phase 2 interventional study of anlotinib + PD-1 inhibitor and PD-1 inhibitor in Esophageal Cancer (EC), sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies testing Immune checkpoint inhibitors in Esophageal Neoplasms — 64 open to participants now, 87 under way, 9 of them phase 3. A drug class: Immune checkpoint inhibitors · Esophageal Neoplasms.

Planned enrollment
43rd of 152
112 · median 54
Started
2026
with 7 others
Phase 2
94 of 152
48 open now
Primary completion
2029-10
later than 80 of 86 live
Registered
152nd of 152
by date
Lead sponsor
5 of 152
Sun Yat-sen University

Among the 152 studies testing Immune checkpoint inhibitors in Esophageal Neoplasms, this one is the 43rd largest by planned enrollment, is one of 8 that started in 2026, is one of 94 in phase 2, reaches primary completion later than 80 of the 86 other live ones, and was the 152nd registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

64 of the 152 studies testing Immune checkpoint inhibitors in Esophageal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

58 more — sign in →

By country, each count listing its studies:

All 64 open studies →

About Immune checkpoint inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies testing Immune checkpoint inhibitors in Esophageal Neoplasms, or all of them as a file.
02

Study summary

Chemotherapy combined with PD-1 inhibitor immunotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC), yet patient prognosis remains unsatisfactory, with a median PFS of only about 6 months and a 1-year PFS rate of only 25%. Adding anlotinib maintenance therapy on top of PD-1 inhibitor immunotherapy maintenance after chemoimmunotherapy may improve progression-free survival and overall survival. We plan to conduct a randomized, multicenter, open-label Phase II study of anlotinib combined with PD-1 inhibitor maintenance therapy versus PD-1 inhibitor monotherapy maintenance in advanced ESCC. A total of 112 patients with unresectable locally advanced, recurrent, or metastatic ESCC are planned to be enrolled. After enrollment, patients will receive either anlotinib combined with PD-1 inhibitor maintenance therapy or PD-1 inhibitor monotherapy maintenance, with a maximum treatment duration of 2 years. This study aims to evaluate the efficacy and safety of anlotinib combined with PD-1 inhibitor maintenance therapy in advanced ESCC by comparing it with the PD-1 inhibitor monotherapy maintenance group, further optimizing the comprehensive treatment model for esophageal cancer.

03

Conditions studied

  • Esophageal Cancer (EC)

Keywords

  • Esophageal Cancer
  • Immunotherapy
  • Anlotinib
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed esophageal squamous cell carcinoma;
  2. Unresectable locally advanced, recurrent, or esophageal squamous cell carcinoma that has not received prior systemic therapy, or recurrence more than 6 months after completion of (neo)/radical therapy;
  3. Patients who have completed 4-6 cycles of inhibitor combined with platinum-based doublet chemotherapy, who may receive local therapy if the investigator determines a benefit from local treatment, and who have not progressed after the above treatment;
  4. Enrollment window: randomization must be performed within 42 days after completion of the last treatment (including local therapy);
  5. Expected survival greater than 3 months;
  6. Age 18-75 years;
  7. performance status score of 0-1;
  8. Laboratory tests within 7 days before the first dose must meet the following requirements: Hematology: neutrophils ≥1.5×10\^9/L, ≥75.0×10\^9/L, ≥80 g/L; Liver function: total ≤1.5 × , /AST ≤2.5 × ULN (≤5 × ULN if liver metastasis is present); Renal function: serum creatinine ≤1.5 × ULN or >60 mL/min; Coagulation function: (INR) or prothrombin time (PT) ≤1.5 × ULN; no concomitant severe organic disease;
  9. The patient understands the details of the trial and has signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to the study drug or to any drug administered in connection with this trial;
  2. Patients who can be cured by surgery or radiotherapy;
  3. Endoscopic or imaging findings indicating obvious deep ulceration of the esophageal lesion; or obvious invasion of adjacent vital organs (such as the aorta or trachea) by the tumor with a very high risk of bleeding or perforation; or formation of an esophageal-tracheal fistula/esophageal-mediastinal fistula;
  4. Presence of complete esophageal obstruction requiring interventional treatment; prior esophageal or tracheal stent placement before enrollment; or presence of factors that significantly affect the absorption of oral drugs (anlotinib), such as inability to swallow tablets, chronic diarrhea, or intestinal obstruction;
  5. Prior treatment with anlotinib; or treatment with other VEGF small-molecule tyrosine kinase inhibitors (TKIs) within 6 months before the first dose (Note: patients who received other VEGF TKIs during (neo)/radical therapy and whose last dose was more than 6 months before this recurrence/progression may be enrolled);
  6. Patients who experienced grade ≥3 immune-related adverse events (irAEs) during inhibitor combined with chemotherapy, or for whom the investigator considers continued PD-1 inhibitor treatment inappropriate due to toxicities;
  7. Presence of symptomatic or meningeal (Note: patients whose brain metastases have been locally treated and remained stable for at least 4 weeks before enrollment without the need for to reduce intracranial pressure may be allowed to enroll);
  8. Patients with a history of other besides esophageal cancer before enrollment, except for melanoma skin cancer, carcinoma in situ of the cervix, or cured early-stage prostate cancer;
  9. Poor blood pressure control despite antihypertensive medication (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg); or patients using two or more antihypertensive drugs to control blood pressure; patients with a history of hypertensive crisis or hypertensive encephalopathy;
  10. Severe cardiovascular disease: myocardial infarction, severe/unstable angina, class III-IV heart failure, (LVEF) \<50% on echocardiography, severe arrhythmia requiring pharmacological intervention, or prior coronary/peripheral artery bypass grafting within 6 months before enrollment;
  11. Bleeding tendency: active bleeding within 2 months before screening (such as gastrointestinal bleeding, hematemesis, melena, etc., with a daily blood loss ≥2.5 mL); or patients with abnormal coagulation function, a bleeding tendency, or currently receiving thrombolytic or anticoagulant therapy (except prophylactic use of low-dose aspirin or low-molecular-weight heparin);
  12. History of thrombosis: arterial or venous thrombotic events within 6 months before enrollment, such as cerebrovascular accident (including ), deep vein thrombosis, or pulmonary embolism;
  13. High renal risk: patients with urine protein ≥++ on urinalysis and confirmed 24-hour urinary protein >1.5 g;
  14. Surgery and trauma: major surgery (such as thoracotomy or laparotomy) within 4 weeks before the first dose, or presence of long-term non-healing wounds or fractures, or expected need for major surgery during the study period;
  15. Active infection: presence of active infection requiring intravenous systemic anti-infective therapy, or known active tuberculosis;
  16. Immune-related deficiency: known history of immunodeficiency, including positive test, or other acquired or congenital immunodeficiency diseases, or a history of solid organ transplantation;
  17. Female patients who are pregnant or breastfeeding;
  18. Investigator's judgment: presence of severe concomitant diseases (such as uncontrolled diabetes, severe liver or kidney disease, etc.), psychiatric disorders, or psychological, family, social, or other factors that the investigator considers may jeopardize patient safety and compliance.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Anlotinib + PD-1 inhibitor maintenance therapy arm

    Anlotinib combined with immunotherapy maintenance therapy

    Drug: anlotinib + PD-1 inhibitor

  • Other
    PD-1 inhibitor maintenance therapy arm

    Immunotherapy monotherapy maintenance therapy

    Drug: PD-1 inhibitor

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    The time from enrollment until the first occurrence of documented disease progression or death from any cause, whichever occurs first.

    Time frame: From enrollment to the end of treatment at 12 months

Secondary outcomes

  1. Progression-free survival 2

    The time from enrollment to the first occurrence of disease progression on the next line of subsequent therapy or death from any cause, whichever occurs first.

    Time frame: From enrollment to the end of treatment at 12 months

  2. Overall survival

    The time from enrollment until death from any cause.

    Time frame: From enrollment to the end of treatment at 12 months

  3. DoR (Duration of Response)

    The time from enrollment or the first documentation of objective tumor response (complete response \[CR\] or partial response \[PR\]) to the first occurrence of documented disease progression or death from any cause, whichever occurs first.

    Time frame: From enrollment to the end of treatment at 12 months.

  4. Treatment-related adverse events

    Incidence of treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: From enrollment to the end of treatment at 12 months.

  5. Quality of Life

    Quality of life was assessed using the EORTC QLQ-C30 questionnaire.

    Time frame: From enrollment to the end of treatment at 12 months.

Other outcomes

  1. Correlation between PD-L1 and overall survival

    The correlation between pretreatment PD-L1 by immunohistochemistry and overall survival.

    Time frame: From enrollment to the end of treatment at 12 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2029, 36 months later.

Of 174 non-industry phase 2 interventional studies under Esophageal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 85. This study's planned 36 months is below that.

Counting every sponsor, half of 198 studies reached it within 52 months; a quarter within 33 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 7, 2026
StartEst.
Oct 12, 2026
Primary completionEst.
Oct 31, 2029
CompletionEst.
Oct 31, 2031
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863141
Collaborators
Sun Yat-Sen University Cancer Center, Jieyang People's Hospital, Jiangmen Central Hospital, Zhongshan People's Hospital, Guangdong, China, Guangdong Second Provincial General Hospital, Cancer Hospital of Guangdong Medical University
Responsible party
Bao Yong (Dr., Sun Yat-sen University) — Principal investigator
First posted
Oct 7, 2026
Start date
Oct 12, 2026 (estimated)
Primary completion
Oct 31, 2029 (estimated)
Completion
Oct 31, 2031 (estimated)
Last update
Oct 7, 2026

Study contacts

Yong Bao, MD
Contact
baoyong@mail.sysu.edu.cn
8602087338692

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anlotinib · Immune checkpoint inhibitors

Start the discussion